Intensity Modulated Radiation Therapy (IMRT) MP9426

Covered Service: Yes—when meets criteria below

Prior Authorization Required: Yes—as shown below

Additional Information: None

Prevea360 Health Plan Medical Policy:

1.0 Intensity-modulated radiation therapy (IMRT) requires prior authorization through the Health Services Division and is considered medically necessary when one or more of the following conditions are present:

1.1 The target volume is in close proximity to critical structures that must be protected;

1.2 The volume of interest must be covered with narrow margins to adequately protect immediately adjacent structures;

1.3 An immediately adjacent area has been previously irradiated and abutting portals must be established with high precision to avoid damage to critical organs such as bowel, bladder, spinal cord or lung;

1.4 The target volume is concave or convex, and critical normal tissues are within or around that convexity or concavity;

1.5 Dose escalation is planned to deliver radiation doses in excess of those commonly utilized for similar tumors with conventional treatment.

2.0 IMRT is considered medically necessary ANY for the following indications if 1.0 has been met:

2.1 Anal cancer;

2.2 Advanced or low lying rectal cancer;

2.3 Anaplastic thyroid cancer;

2.4 Brain tumors in close proximity to critical structures;

2.5 Esophageal cancer where dose exceeds 50 Gy;

2.6 Gallbladder cancer where dose exceeds 50 Gy;

2.7 Head and neck cancer excluding T1 and T2 glottic cancer;

2.8 Left breast cancer if the lesion is in close proximity to the heart or other cardiovascular structures;
Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member’s benefit certificate or policy.

2.9 Lung cancer if the lesion is in close proximity to the heart or other critical structures;
2.10 Pancreatic cancer where dose exceeds 50 Gy;
2.11 Postoperative radiation to pelvis for endometrial cancer;
2.12 Prostate cancer;
2.13 Primary, metastatic or benign tumors of the central nervous system, including the brain, brain stem, and spinal cord;
2.14 Primary, metastatic tumors of the spine where spinal cord tolerance may be exceeded by conventional treatment,
2.15 Primary metastatic benign lesions to the head and neck area including the aerodigestive tract, orbits, salivary glands, sinuses and skull base;
2.16 Gastric cancer;
2.17 Gynecologic malignancies e.g. uterus, cervix, ovary, fallopian tube;
2.18 Liver metastasis;
2.19 Lymphoma, involving one or more of the following:
   2.19.1 Eye (primary monocular)
   2.19.2 Lung
   2.19.3 Mediastinum, in proximity to lung and heart
   2.19.4 Nasal cavity
   2.19.5 Paranasal sinuses
   2.19.6 Parotid or other salivary gland
   2.19.7 Thyroid
   2.19.8 Stomach
2.20 IMRT may be necessary in lung cancer cases involving bilateral mediastinal involvement, extension to the midline of the mediastinum, cardiac involvement, or tumor abutting or involving vertebrae or brachial plexus, or great vessels.

3.0 There are some indications for which there is insufficient data to conclude that IMRT is safe and effective, therefore, IMRT is considered experimental/investigational and therefore is not medically necessary for the following indications:
3.1 Right breast cancer
3.2 Colon cancer
3.3 Lung cancer other than that described in criteria 2.9
3.4 Secondary bone and articular cartilage cancer
Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member’s benefit certificate or policy.

<table>
<thead>
<tr>
<th>Committee/Source</th>
<th>Date(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Originated: Medical Director Committee/Medical Affairs</td>
<td>September 28, 2011</td>
</tr>
<tr>
<td>Revised: Medical Director Committee/Medical Affairs</td>
<td>January 16, 2013</td>
</tr>
<tr>
<td></td>
<td>August 20, 2014</td>
</tr>
<tr>
<td></td>
<td>June 21, 2017</td>
</tr>
<tr>
<td></td>
<td>July 19, 2017</td>
</tr>
<tr>
<td></td>
<td>August 15, 2018</td>
</tr>
<tr>
<td>Reinstated and Revised: Medical Policy Committee/Quality and Care Management Division</td>
<td>December 21, 2016</td>
</tr>
<tr>
<td>Reviewed: Medical Director Committee/Medical Affairs</td>
<td>August 15, 2012</td>
</tr>
<tr>
<td></td>
<td>January 16, 2013</td>
</tr>
<tr>
<td></td>
<td>July 17, 2013</td>
</tr>
<tr>
<td></td>
<td>July 16, 2014</td>
</tr>
<tr>
<td></td>
<td>August 20, 2014</td>
</tr>
<tr>
<td></td>
<td>December 21, 2016</td>
</tr>
<tr>
<td></td>
<td>June 21, 2017</td>
</tr>
<tr>
<td></td>
<td>July 19, 2017</td>
</tr>
<tr>
<td>Deleted: Medical Director Committee/Medical Affairs</td>
<td>July 15, 2015</td>
</tr>
</tbody>
</table>

Published/Effective: 09/01/2018